Home SVCC                                                  Area: English - Español - Português

Effectiveness of Lasero-Medicamentosive
Ischemic Heart Disease Treatment

Amirov, Nail; Abdrahmanova, Alsu;
Amirova, Renata; Pigalova, Svetlana

Interreginional Clinical Diagnostic Centre, Kazan, Russia

Background: Quests of new methods in IHD (ischemic heart disease) treatment revealed the effectiveness of laserotherapy (LT).

Objectives: We have studied the dynamics of clinical data under the influence of HeNeLaser depending on combination of medicaments in treatment of IHD.

Materials and methods: Observed 93 patients with IHD (69 men, 24 women) at the age of 57,71 + 0,83 years. In order to reveal rational drugs treatment combinations patients were divided into 4groups: 1-"Nitrates+IACE+Aspirin"; 2-"Nitrates+Aspirin"; 3-"Nitrates+BKK"; 4-"Nitrates+BKK+CG". Randomized -59patients received LT and 34-traditional medicamentosive treatment (TMT). LT was conducted by apparatus ALOK-1 (λ = 0,63mkm, continuous regime, power on the lightgye exit 1mVt.) Lightgye was lead in vein 3-5 cm deep. Investigations were carried out before and after treatment.

Results: In 2gr. Received LT QRS increase () from 0,09 ± 0,01 to 0,11 ± 0,01 sec recorded (p<0,05), in 3gr. against LT background-heartbeat decrease from 81 ± 1,52 to 66 ± 3,95 per min (p<0,05) and QT from 0,35 ± 0,01 to 0,39 ± 0,001 sec (p<0,05), on the TMT background-Produce from 0,1 ± 0,0001 sec to 0,08 + 0,0001 sec (p<0,05) on ECG in dynamics; for patients who did not receive LT in 4gr. Established cholesterol level (H) decrease from 5,50 ± 0,3 to 3,85 ± 0,12 mmole\l. (p<0,05). During before and after LT data comparing, in dependence of medicaments used in complex treatment established: in1gr. fibrinogen A decrease () from 4,37 ± 0,89 to 2,7 ± 0,01 mekv\l (p<0,050); in 2gr ß-lipoproteides (ßLP) from 67,47 ± 5,37 to 85,9 ± 7,04 ed. (p<0,05), in the same group recorded RR lengthening from 0,8 ± 0,01 to 0,89 ± 0,03 sec.(p<0,05) and heartbeat raring from 80,7 ± 1,46 to 67 ± 1,45 per min (p<0,01); in 3gr.-QT lengthening from 0,36 ± 0,001 sec. to 0,39 ± 0,0001 sec (p<0,001); in 4gr .under LT background-urea (U) from 5,67 ± 0,44 to 2,77 ± 0,02 mmole\l (p<0,01), in the same group under LT influence noted Erythrocyte Sedimentation Reaction (ESR) delay from 10 ± 2,4 to 8,8 ± 2,05 mm\h (p<0,01), leucocytosis (L) from 6,9 ± 0,55 to 4,86 ± 0,27 thousands (p<0,05) during before and after TMT data comparing in all groups established: in 1gr. ßLP from 57,63 ± 1,68 to 66,33 ± 2,02 mmole\l. (p<0,05); LDG level from 237,08 ± 14,43 to 121,33 ± 3,04 E\l. (p<0,01); KFK level from 129,4 ± 15,80 to 53,67 ± 9,47 E\l. (p<0,05); in 2gr. increase in frequency of heartbeat from 80,68 ± 2,37 to 98,5 ± 1,46 (p<0,05); triglycerides level (TG) from 1,61 ± 0,05 to 2,4 ± 0,01 mmole\l (p<0,05); in 3gr level L from 6,4 ± 0,3 to 7,6 ± 1,4 th. (p<0,001) and QRST shortness from 0,36 ± 0,0003 to 0,33 ± 0,01 sec (p<0,001); in4 gr. level H from 5,54 ± 0,11 to 87 ± 0,12 mmole\l (p<0,01), KFK from 129,4 ± 15,8 to 59 ± 2,24 E\l (p<0,05) and ßLP from 57,63 ± 1,68 to 43,5 ± 0,18 E\l. (p<0,05); PTI level from 82,38 ± 0,12 to 76,67 ± 0,86 (p<0,05).

Discussion: During studying and comparing data normalization in proper groups (1,2,3,4), among patients received only TMT and with addition LT established: in 2gr. after LT recorded ßLPlevel on 43%, the same time in control group for 20% (p<0,05); in 4 gr: level M in investigation group on 54%, during in control group level M on 0,9% (p<0,001); bilirubine (B) level in investigation group on 70%, the same time in control group B on 11% (p<0,050); level L received LT on 24%, among patients did not receive LT (control group) on 4,6% (p<0,05); PTI level on the LT background (investigation group) on 65%, the same time PTI level in control group on 6,9%.

Conclusion: The data received by us show the most beneficial influence HeNeL evince in 1, 3, 4 groups.

 

Top

Questions, contributions and commentaries to the authors: send an e-mail message (up to 15 lines, without attachments) to coronary-pcvc@fac.org.ar, written either in English, Spanish, or Portuguese.


2nd Virtual Congress of Cardiology

Dr. Florencio Garófalo
Steering Committee
President
Dr. Raúl Bretal
Scientific Committee
President
Dr. Armando Pacher
Technical Committee - CETIFAC
President
fgaro@fac.org.ar
fgaro@satlink.com
rbretal@fac.org.ar
rbretal@netverk.com.ar
apacher@fac.org.ar
apacher@satlink.com

Copyright© 1999-2001 Argentine Federation of Cardiology
All rights reserved

 

This company contributed to the Congress: